comparemela.com

Latest Breaking News On - Khurram jamil - Page 1 : comparemela.com

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29.03.2024 - NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended .

Richard-uihlein
Chris-calabrese
Jack-callicutt
Khurram-jamil
Kevin-gardner
Benjamins-carson
Pol-boudes
Company-annual-report-on-form
Belapectin-program
Drug-administration
Company-contact

Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K -March 29, 2024 at 07:59 am EDT

Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31,.

Khurram-jamil
Chris-calabrese
Benjamins-carson
Jack-callicutt
Joel-lewis
Pol-boudes
Richard-uihlein
Kevin-gardner
Nasdaq
Company-annual-report-on-form
Exchange-commission

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target .

Japan
United-states
Pakistan
Polf-boudes
Chris-calabrese
Khurram-jamil
Jack-callicutt
Kevin-gardner
Company-annual-report-on-form
Nasdaq
Galectin-therapeutics-inc
King-edward-medical-university-at-lahore

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting

/PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three scientific abstracts evaluating.

Pennsylvania
United-states
Philadelphia
Dublin
Ireland
Americans
American
Juan-carlosq-velez
Prnewswire-mallinckrodt
Derek-belz
Hanim-wadei
Jamilk-terlipressin

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

/PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three posters detailing findings from.

Canada
United-states
Vancouver
British-columbia
United-kingdom
Dallas
Texas
Dublin
Ireland
Palo-alto
Americans
British

vimarsana © 2020. All Rights Reserved.